Markers in Follicular Fluid and in Embryo Culture Medium as a Marker of Oocyte and Embryo Quality
1 other identifier
observational
220
1 country
1
Brief Summary
Assessment of the quality of follicular fluid and early embryo via chemical markers.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Dec 2017
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
November 2, 2017
CompletedFirst Posted
Study publicly available on registry
November 22, 2017
CompletedStudy Start
First participant enrolled
December 11, 2017
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2019
CompletedStudy Completion
Last participant's last visit for all outcomes
November 1, 2019
CompletedJanuary 31, 2019
January 1, 2019
1.5 years
November 2, 2017
January 30, 2019
Conditions
Outcome Measures
Primary Outcomes (1)
Different markers discriminating the studied groups.
High correlation between the studied markers and the currently used morphological assessment of the quality of embryos and oocytes will define the potential of the studied markers as a mean for embryo and quality assessment. The current study is pioneer in the field of assessment of embryos and follicles and this group of markers have not been studied previously, therefore we prefer not to clarify more details
two years
Study Arms (2)
High and low grade embryos
The distribution for the high and low grade embryos is based on common morphological grading criteria.
High and low quality follicles
The distribution for the high and low grade oocytes is based on common morphological grading criteria and on different features of the participants such as age.
Eligibility Criteria
Patients undergoing IVF procedures at Carmel Medical Center
You may qualify if:
- Patients undergoing IVF procedures at Carmel Medical Center and are able to sign an informed consent form.
- Female patients age 18-45
You may not qualify if:
- Women with any malignancy
- Patient's request to be withdrawn from the study.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Carmel Medical Center
Haifa, 34362, Israel
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Martha Direnfeld, Prof.
Carmel Medical Center
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- OTHER
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 2, 2017
First Posted
November 22, 2017
Study Start
December 11, 2017
Primary Completion
June 1, 2019
Study Completion
November 1, 2019
Last Updated
January 31, 2019
Record last verified: 2019-01
Data Sharing
- IPD Sharing
- Will not share